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Abstract
Background: Multiple (epi)genetic defects affecting the expression of the imprinted genes within the 11p15.5
chromosomal region underlie Silver–Russell (SRS) and Beckwith–Wiedemann (BWS) syndromes. The molecular
diagnosis of these opposite growth disorders requires a multi-approach flowchart to disclose known primary and
secondary (epi)genetic alterations; however, up to 20 and 30 % of clinically diagnosed BWS and SRS cases remain
without molecular diagnosis. The complex structure of the 11p15 region with variable CpG methylation and low-rate
mosaicism may account for missed diagnoses. Here, we demonstrate the relevance of complementary techniques for the
assessment of different CpGs and the importance of testing multiple tissues to increase the SRS and BWS detection rate.
Results: Molecular testing of 147 and 450 clinically diagnosed SRS and BWS cases provided diagnosis in 34 SRS and 185
BWS patients, with 9 SRS and 21 BWS cases remaining undiagnosed and herein referred to as “borderline.” A flowchart
including complementary techniques and, when applicable, the analysis of buccal swabs, allowed confirmation of the
molecular diagnosis in all borderline cases. Comparison of methylation levels by methylation-specific multiplex
ligation-dependent probe amplification (MS-MLPA) in borderline and control cases defined an interval of H19/IGF2:IG-DMR
loss of methylation that was distinct between “easy to diagnose” and “borderline” cases, which were characterized by
values ≤mean −3 standard deviations (SDs) compared to controls. Values ≥mean +1 SD at H19/IGF2: IG-DMR were
assigned to borderline hypermethylated BWS cases and those ≤mean −2 SD at KCNQ1OT1: TSS-DMR to hypomethylated
BWS cases; these were supported by quantitative pyrosequencing or Southern blot analysis. Six BWS cases suspected to
carry mosaic paternal uniparental disomy of chromosome 11 were confirmed by SNP array, which detected mosaicism till
10 %. Regarding the clinical presentation, borderline SRS were representative of the syndromic phenotype, with exception
of one patient, whereas BWS cases showed low frequency of the most common features except hemihyperplasia.
Conclusions: A conclusive molecular diagnosis was reached in borderline methylation cases, increasing the detection
rate by 6 % for SRS and 5 % for BWS cases. The introduction of complementary techniques and additional tissue analyses
into routine diagnostic work-up should facilitate the identification of cases undiagnosed because of mosaicism,
a distinctive feature of epigenetic disorders.
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Background
The 11p15.5 chromosomal region contains two clusters of
imprinted genes, the monoallelic expression of which is
independently regulated by cis-acting differentially meth-
ylated regions (DMRs) or imprinting control centers
(ICR), ICR1 (alias H19/IGF2:IG-DMR) and ICR2 (alias
KCNQ1OT1:TSS-DMR), corresponding to sequences
methylated on one parental allele [1]. H19/IGF2:IG-DMR,
which is located upstream of the H19 promoter, controls
the telomeric cluster containing the IGF2 and H19 genes,
which are expressed on the paternal and maternal chromo-
somes, respectively. KCNQ1OT1:TSS-DMR, lying within
an intron of the KCNQ1 gene, regulates the centromeric
cluster containing the CDKN1C and KCNQ1 genes, which
are expressed by alleles of maternal origin, and the KCNQ1
antisense transcript KCNQ1OT1, which is expressed on the
paternal allele [2–4]. Multiple genetic and epigenetic
defects lead to the congenital Silver–Russell (SRS) and
Beckwith–Wiedemann (BWS) syndromes, which are char-
acterized by opposite growth disorder phenotypes and im-
balances in the expression levels of the resident imprinted
genes. The variety of (epi)genetic alterations and the com-
plex structural organization of the 11p15.5 region account
for the difficult molecular diagnostics of these clinically and
genetically heterogeneous disorders [5, 6]. Currently, loss of
methylation (LoM) of the paternal ICR1-H19 locus is
present in >50 % of SRS patients, whereas gain of
methylation (GoM) of the maternal ICR1-H19 is ob-
served in 5 % of BWS patients and has recently been
suggested to be more common than previously thought
[7]. More than 50 % of BWS patients display LoM at
the maternal KCNQ1OT1:TSS-DMR, leading to biallelic
expression of the KCNQ1OT1 long non-coding tran-
script and silencing of the active maternal alleles. More
than 20 % of BWS patients carry mosaic paternal uni-
parental disomy of chromosome 11 (upd(11)pat), with a
great variability in the level and extent of isodisomy.
After adding 5–10 % of BWS patients positive for loss-
of-function CDKN1C mutations and a small (1–2 %) frac-
tion of 11p familial or de novo rearrangements causing
duplication of the paternal chromosome, up to 20 % of
clinically diagnosed BWS cases remain without a molecu-
lar diagnosis [8, 9]. A similar situation occurs for SRS,
where 10 % of the patients carry maternal upd7 and a tiny
fraction (up to 4 %), slightly higher than that for BWS,
carry structural rearrangements of the maternal chromo-
some 11p [5, 10]. In parallel, familial forms of SRS bear
gain of function mutations of the PCNA domain of
CDKN1C [11], further confirming that opposed functional
mutations underlie the opposite phenotypes. Because
several primary or secondary epigenetic mechanisms asso-
ciated with BWS and SRS occur at a low mosaic level,
complementary techniques interrogating different CpGs
of the target genes and their flanking regions, including
quantitative methylation-specific pyrosequencing [12, 13]
and in some cases analysis of a tissue other than blood
[14], are recommended to confirm uncertain results. The
common mosaic paternal UPD11 underlying BWS usually
requires parents for proband microsatellite analysis; how-
ever, SNP array might highlight overlooked low mosaic
upd [15], in addition to providing fine mapping of the
recombination breakpoints [16]. Similarly, detection of the
rare but observable structural rearrangements or copy
number variations causing subtle imbalances of the subte-
lomeric 11p15.5 region requires the integrated application
of multicolor fluorescence in situ hybridization (FISH),
high-resolution array comparative genomic hybridization
(CGH), or SNP array [17–20]. Cis- and trans-acting
factors responsible for complex interactions between the
11p15.5 imprinted genes have been identified in both
BWS and SRS [7, 21, 22]; however, they are not included
in the current diagnostic flowchart as no precise informa-
tion is available on the fraction of cases accounted for by
these mechanisms. Although this point is being addressed
by ongoing research, diagnostic laboratories must com-
bine all the indicated approaches to obtain the highest
possible detection rate (>80 %) of (epi)genetic alterations
in SRS and BWS.
In the course of our diagnostic activity on 450 patients
within the BWS spectrum and 147 SRS, including 130
likely and 17 unlikely SRS [23], we encountered a set of
21 BWS and 9 SRS cases, comprehensive of an unlikely
case, in which a conclusive molecular diagnosis was
lacking upon a standard (epi)genetic test. These cases
are herein referred to as “borderline” and are the main
subjects of the present study. They exemplify the diffi-
culties in confirming the clinical diagnosis and under-
score the need to combine Southern blotting (SB) with
methylation-specific multiplex ligation-dependent probe
amplification (MS-MLPA) and bisulphite pyrosequencing
and microsatellite segregation analysis with SNP array using
patients’ blood and, when possible, additional tissues, to ob-
tain an unequivocal molecular diagnosis. Identification of
low-level mosaic upd(11)pat, which implies a high cancer
risk in BWS [24] and in its mildest phenotypic end (i.e.,
pure isolated hemihyperplasia (IH)) [25] has a strong trans-
lational impact, as it allows proper oncological surveillance
and patient management.
Results
Figure 1 shows a schematic representation of the complex
architecture of the 11p15.5 imprinted region, including
H19/IGF2:IG-DMR, with its cluster organization (CTS1-
CTS7) and IGF2:ex9-DMR, IGF2:alt-TSS-DMR (a) and
KCNQ1OT1:TSS-DMR (b). As shown for both imprinted
domains, the DMRs targeted by the probes used in SB,
MS-MLPA, and pyrosequencing primers [8, 12, 26, 27] are
different, indicating that the available tools are not
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redundant, but rather complementary, for investigat-
ing the 11p15.5 methylation profile.
Definition of standard parameters for MS-MLPA
MS-MLPA is currently the most rapid and robust tech-
nique to assess methylation. Therefore, before combin-
ing it with other techniques, we established the proper
range of values in the normal population. Control DNA
obtained from blood samples of 50 normal individuals
was used to calculate for each probe the mean value
(±1–3 standard deviation (SD) points). As shown in
Additional file 1: Table S1, the mean values varied accord-
ing to the probes and the range from the lowest to the
maximum values. All samples fell within the 2 SD range
for both H19/IGF2:IG-DMR and KCNQ1OT1:TSS-DMR,
allowing definition of the range in healthy individuals.
Complementary use of SB, MS-MLPA, and
pyrosequencing
Various 11p15.5 targeted techniques, such as Southern
blot (SB), MS-MLPA, and pyrosequencing, were com-
bined to compare their sensitivity in mosaicism detec-
tion. Despite the multi-disciplinary technical approach,
additional tissues were analyzed in borderline cases to
obtain an unequivocal molecular diagnosis.
The clinical diagnosis of SRS was confirmed by genetic
testing in 43 of 147 patients (29 %) with suspected SRS.
Of these, seven patients carried upd(7)mat (4.8 %),
one of which scored as unlikely SRS, whereas paternal
Fig. 1 Schematic of the 11p15 imprinted region. ICR1 comprising H19/IGF2:IG-DMR, organized into the two CTS1-3 and CTS 4–6 clusters, plus the
proximal CTS7, IGF2:ex9-DMR, and IGF2:alt-TSS-DMR (a) and ICR2 comprising KCNQ1OT1:TSS-DMR (b) are depicted. Red lines ending with arrowheads point
to the DMRs. The HpaII sites, widely distributed across H19/IGF2:IG-DMR, are indicated by the vertical H bars; letters in the boxes represent CpG sites analyzed
by SB. The Csp6I (a), BamHI, and NotI (b) sites are indicated by the vertical C, B, and N bars, respectively. Green horizontal bars indicate the probes for SB, blue
vertical bars indicate the MLPA probes (dashed for CNVs and solid for methylation status), and solid purple bars indicate the pyrosequencing target regions
[12]. The numbers in brackets of MLPA methylation probes refer to those indicated with the relative code in Fig. 2f, g
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H19 hypomethylation was detected in the remaining
36 (24.4 %) cases. Mosaic H19/IGF2:IG-DMR LoM
was definitely detected in 27 cases by SB and those
samples were used for the set up of MS-MLPA (since
it was available) and pyrosequencing tests. Concerning
the remaining nine SRS, (eight clinically likely and
one unlikely) belong to the borderline cases focus of
this study. Additional file 2: Table S2 shows how
many SRS patients achieved a molecular diagnosis by
single and/or combined SB/MS-MLPA/pyrosequencing
techniques.
The clinical diagnosis of BWS was confirmed genetically
in 206 of 450 patients, accounting for a detection rate of
46 %. The epigenetic defects were detected by the use of a
single technique with definite values in 120 (27 %) mosaic
maternal LoM at KCNQ1OT1:TSS-DMR patients, in nine
(2 %) mosaic maternal GoM at H19/IGF2:IG-DMR and in
46 cases of mosaic paternal UPD including seven cases
with additional altered copy number variants (CNVs) indi-
cative of a microdeletion/duplication [18, 28], [unpub-
lished]; some of these cases were used to validate
alternative techniques as detailed in Additional file 2:
Table S2. Despite the SB has been now overlooked by
more recent techniques, in the past, it was the only avail-
able test.
Thanks to the complementary technical approaches
used the diagnosis could be also confirmed in 9 SRS and
in 21 BWS cases with borderline methylation levels. The
availability of buccal smears was fundamental in sustain-
ing the molecular diagnosis of 8 BWS and 3 SRS cases
within the borderline subset and definitely allowed to
sort out from the positive set a couple of cases.
Low-level mosaic epimutations
The challenge for molecular diagnosis raised by low-level
mosaic epimutations can be addressed by using complemen-
tary techniques and multiple tissues. Figure 2 provides repre-
sentative examples of low-level mosaic epimutations in SRS
and BWS. The autoradiograms of the cases with borderline
H19/IGF2:IG-DMR and KCNQ1OT1:TSS-DMR band pat-
terns are shown in Fig. 2a–e. The respective SB densitomet-
ric methylation indexes and methylation values obtained by
pyrosequencing in 6 of 9 borderline SRS cases and 20 of 21
borderline BWS cases are also shown. The MS-MLPA
methylation ratio of all SRS/BWS samples with borderline
methylation values are provided in Additional file 3: Table
S3. Figure 2f, g displays graphs summarizing the distribution
of the values obtained by the MS-MLPA HhaI probes for
H19/IGF2:IG-DMR and KCNQ1OT1:TSS-DMR in samples
with different degrees of hypo/hypermethylation, including
the borderline SRS and BWS cases. The methylation values
in the control cohort were distributed within mean values
±2 SD points. The four HhaI MLPA probes in H19/
IGF2:IG-DMR hypomethylated SRS cases had almost all
values ≤mean −3 SDs (Fig. 2f). MS-MLPA showed in the
borderline cohort values slightly below the cut-off, which
were supported by SB (see, i.e., cases 1 and 2) and by pyrose-
quencing (cases 3 and 6) (Fig. 2a). The mean values among
the four probes of MS-MLPA (Additional file 3: Table S3)
may give a misleading result (i.e., BWS cases 10 and 13) so
we always considered the single values for each probe. The
detection of at least two probes lying outside the interval of
normal samples indicates possible epimutations at a low mo-
saic rate and needs to be further validated. On the other
hand, the methylation ratios in H19/IGF2:IG-DMR hyper-
methylated borderline BWS cases partially overlapped with
those of the normal population for some of the probes; ac-
cordingly, cases with values ≥mean +1 SD were considered
to be hypermethylated. The three patients showing
GoM at H19/IGF2:IG-DMR at borderline values by
MS-MLPA were supported by SB (cases 1 and 3) and
by pyrosequencing (case 1 at DMR2 and cases 2 and 3
at H19 prom) (Fig. 2b–e).
Of the eight patients with KCNQ1OT1:TSS-DMR
LoM with values at the cut-off by MS-MLPA, case 10
was only supported by SB, cases 4 and 6 only by pyrose-
quencing and cases 5, 7, 8, and 9 by both SB and pyrose-
quencing (data reported in Additional file 3: Table S3)
(Fig. 2c).
Whenever possible, cases close to the cut-off by the
three techniques (SRS-1, SRS-2, and SRS-9 and BWS-1,
BWS-2, BWS-6, BWS-7, BWS-11, BWS-15, BWS-16,
and BWS-17) were resolved by analyzing mouth swabs,
which provided clear-cut results in some cases. In pa-
tient SRS-1 SB, MS-MLPA and pyrosequencing consist-
ently detected slight hypomethylation associated with
copy number gain, which is suggestive of microduplica-
tion (Fig. 2h). The H19 methylation ratio was lower in
the buccal swab test than in the blood test, confirming
the occurrence of the epimutation.
Low-level mosaic upd(11)pat
Out of 46 BWS patients with both KCNQ1OT1:TSS-DMR
LoM and H19/IGF2:IG-DMR GoM, 42 were confirmed to
be mosaic upd(11)pat by 11p15.5 microsatellite analysis,
whereas four carried chromosomal rearrangements de-
tected by molecular cytogenetic techniques [18] (unpub-
lished). Slight epimutations were suspected in ten
additional cases, as suggested by borderline ratios between
the paternal and the maternal alleles in the microsatellite
analysis [29], thus hampering a conclusive molecular diag-
nosis. These cases showed the lowest degree of mosaicism,
revealing uncertain results with each technique. Microsat-
ellite ratios helped us to suspect the diagnosis, but the
conclusive diagnosis was taken after the SNP array test.
Additional file 3: Table S3 highlights the controversial re-
sults obtained by the different techniques.
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To exemplify the doubtful cases, cases 13 and 16 would
have been missed by MS-MLPA, cases 12 and 18 would
have been fully missed by SB, and cases 13, 16, and 20 by
pyrosequencing (Fig. 2d, e). In six of these cases, SNP array
confirmed the low mosaic upd(11)pat rate. As shown by
the profiles in Fig. 3, the extent of segmental UPD was
highly variable, ranging from the entire arm of chromo-
some 11p to only the distal 11p15.5–p15.4 cytobands. The
rate of mosaicism in blood samples was 10 % in half of the
tested patients and from 15 to 20 % in the remaining three
Fig. 2 (Epi)genetic alterations of SRS and BWS borderline (BL) cases assessed by SB, pyrosequencing and MS-MLPA. a Autoradiograms of borderline SRS
patients showing a subtle increase in the density of the unmethylated band for H19/IGF2:IG-DMR. In the borderline BWS patients, autoradiograms show a
slight increase in density at the methylated alleles at the H19/IGF2:IG-DMR (b, d) and at the unmethylated allele at the KCNQ1OT1:TSS-DMR (c, e). Under
each southern lane, methylation indexes (MI) obtained by densitometry quantification are shown and pyrosequencing methylation percentages
are provided for the following probes: ICR1 (a); ICR1, H19 promoter and DMR2 (b); ICR2 (c, e); and ICR1 and H19 promoter (d): see Additional file 1: Table
S1 and the “Methods” sections for the normal ranges and the thresholds accordingly set up. Aberrant methylation values are shown by bold underlined
numbers. The diagrams in f and g show the distribution of MS-MLPA methylation values obtained with the HhaI probes in 50 normal
individuals (Additional file 1: Table S1). The horizontal black bars (left to the control methylation distributions) define the interval between the mean value
and ±1 to 3 SDs. All values at H19/IGF2:IG-DMR and KCNQ1OT1:TSS-DMR are depicted by dots (red for SRS and blue for BWS). Hypomethylated
(SRS), borderline hypomethylated (SRS BL), 15 representative hypermethylated (BWS), and all borderline hypermethylated (BWS BL) are shown
in f, while borderline hypomethylated (BWS BL) and 26 representative hypomethylated (BWS) are shown in g. See Additional file 3: Table S3
for the methylation values of all borderline cases. Due to the limited availability of DNA, BWS borderline case 11 was not included in the figure as investigated
only by pyrosequencing and MS-MLPA (see Additional file 3: Table S3). h The results for borderline SRS-1 obtained by SB, pyrosequencing, and MS-MLPA on
blood and buccal swab DNA. MS-MLPA CNVs are shown, indicating a small sized gain at locus H19/IGF2:IG-DMR
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cases. The clinical phenotype of the six cases solved by SNP
array was consistent with pure IH in BWS-16 and BWS-21
and IH plus one/two additional signs of the BWS spectrum
in BWS-12, BWS-13, BWS-14, and BWS-15. Re-evaluation
of the MS-MLPA values and microsatellite peaks of the
array-SNP-solved cases supported the diagnosis of low-level
upd in the remaining four borderline cases.
The SRS and BWS flowcharts outlined in Fig. 4a, b
summarize the itinerary of the molecular diagnostic work-up
which led to molecular diagnosis in our clinically evaluated
SRS and BWS patients, also including low levels epimutated
and upd(11)pat cases. We suggest to confirm/rule out the
molecular diagnosis of borderline cases by different tech-
niques and, when possible, by testing multiple tissues.
Chromosome 7 upd should follow on the 11p epigenetically
negative SRS cases, while CDKN1C sequencing is recom-
mended in the negative to methylation test BWS cases. Fur-
ther proceedings, to achieve the molecular diagnosis and
match it to the clinical phenotype are outlined too, even if
they have not yet entered in the current diagnostics.
Clinical features of borderline patients
Tables 1 and 2 provide the clinical data of borderline SRS pa-
tients (n= 9, aged 8 months to 13 years) and BWS patients
(n= 21, 11 mosaic epimutated and 10 mosaic upd(11)pat
cases, aged 10 days to 14.5 years). The latter group included
the six BWS patients in which the upd(11)pat diagnosis
needed to be confirmed by SNP array.
All our borderline SRS patients presented with the
characteristic of likely SRS, according to Netchine-
Harbison criteria [23], with the exception of SRS-6, who
did not show any SRS sign except body asymmetry. The
latter was observed in 7/9 (77 %) cases (Table 1). Re-
garding common BWS clinical signs, birth overgrowth
was present in 6/19 (31 %) patients, postnatal over-
growth in 5/20 (25 %), macroglossia in 7/21 (33 %),
hypoglycemia in 6/21 (28 %), and omphalocele in 2 cases
(<1 %). By contrast, hemihyperplasia was observed in
18/21 (86 %) probands and was isolated in three patients
(BWS-16, BWS-17, and BWS-21) and associated with
only a minor BWS sign in six patients (BWS-1, BWS-4,
BWS-6, BWS-12, BWS-14, and BWS-15). Methylation
anomalies at the two ICRs and upd(11)pat were the causa-
tive mechanisms of these borderline cases, mostly lying
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Fig. 3 SNP array Bead Studio output of selected BWS borderline
cases. All the indicated BWS patients, “suspected” by microsatellite
11p15 analysis, are confirmed to carry a mosaic segmental paternal
uniparental disomy (upd(11)pat). Patients are listed from top to
bottom according to decreasing extent of the mosaic isodisomy
(framed in red in the ideogram below each profile). The percentage
of upd(11)pat in the DNA from blood cells, calculated from the array
data as described (see the “Methods” section), ranges from 20 %
(BWS-15, BWS-21) to 15 % (BWS-14) down to 10 % (BWS-12, BWS-13,
and BWS-16)
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at the mildest end of the wide BWS spectrum. Consist-
ent with these observations, the facial dysmorphisms
typical of SRS and BWS were only detected in a few
cases and were absent in others, as shown in Fig. 5. In
line with the variable clinical phenotype of the border-
line BWS patients, unusual findings included intrauter-
ine growth restriction (IUGR), cleft palate, and dilated
submeningial cavities in BWS-3, and renal hypoplasia in
BWS-16. Of 21 BWS borderline patients, two belonged
to monozygotic twin pairs. One of the borderline SRS
patients developed a paravertebral neuroblastoma at age
2.5 years, and two BWS patients developed Wilms
tumor at 2.5 and 4 years, respectively. Two SRS and
two BWS patients were conceived by artificial repro-
ductive techniques.
Discussion
The objective of the present work was to integrate comple-
mentary techniques to improve the identification of SRS
and BWS patients with 11p15 abnormalities whose diagno-
sis may have been missed using standard genetic tests.
Although pyrosequencing of H19/IGF2:IG-DMR and
KCNQ1OT1:TSS-DMR [12, 13] and SNP arrays [15, 16]
are effective techniques for the evaluation of low-level
A B
Fig. 4 Flowcharts for molecular diagnosis of SRS (a) and BWS (b) syndromes. a. The 11p15.5 methylation test targeted to H19/IGF2:IG-DMR is the
first assay and is currently performed by MS-MLPA or pyrosequencing or Southern blot. In cases with borderline methylation values, two or more
combined techniques are useful and if applicable multiple tissues should be tested. Evidence of LoM with normal CNVs confirms the epigenetic
defect, while LoM with altered CNVs suggests a microdeletion/duplication. These cases need to be defined by karyotyping, FISH, or array-based
genomic methods which should be extended to probands’ parents in order to define the recurrence risk. Further proceeding in cases with the
epigenetic defect is represented by the MLID test. Cases with normal 11p15.5 methylation levels are tested by chromosome 7 MS-MLPA and/or
microsatellite analysis to evidence maternal upd(7)mat and possible epimutations. The negative cases are either processed by array-based gen-
omic methods to detect upd at multiple chromosomal regions or sequenced for CDKN1C and IGF2 or addressed to differential diagnoses. b The
11p15.5 methylation test targeted to both H19/IGF2:IG-DMR and KCNQ1OT1:TSS-DMR is the preliminary assay, and alternative options are recommended
according to altered (positive) or borderline results. Microsatellite analysis defines upd, while aberrant CNVs raise the suspicion of unbalanced
translocation/duplication, which should be verified by karyotyping/FISH/array-based methods and, if confirmed, recommend parental analysis.
Further proceedings are represented by MLID test in case of epigenetic defect and genome-wide upd test in case of mosaic paternal upd. Bor-
derline values on a single tissue can be ascertained by the analysis of an additional tissue and techniques, also including SNP array, that may
better explore the region. On negative cases, CDKN1C mutations are then searched to complete the BWS molecular testing. Should the clinical
diagnosis not be confirmed, differential diagnoses have to be taken into account and whole exome deep sequencing and array-based
methods should be considered
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Table 1 Clinical features of borderline Silver–Russell cases
Cases 1 2 3 4 5 6 7 8 9
Sex M M F F M M M M F
Age at last evaluation 6 y 2.9 y 4.1 y 8 y 2.5 y 13 y 1 y 2.6 y 8 m
ART − − + − + − − − −
IUGR + + + + + − + + −
Oligohydramnios nr − − − − − − − −
Weeks at delivery 37 + 4 34 + 6 35 + 4 40 34 42 37 + 2 37 38
Birth weight (g %) 1860 <3 % 1670 <3 % 1970 <10 % 2380 1200 <3 % nr 2000 3 % 2250 5 % 2300 <5 %
Birth length (cm %) 42 <3 % 41 <3 % 41 <3 % 49 39 <3 % nr 43 47 5 % 43 <3 %
CC (cm %) 33 10 % 32 33.5 75 % 33 31 50 % nr nr 33 10 % nr
Weight (%) at last evaluation <5 % 3 % <3 % <3 % <3 % 50−75 % <3 % <5 % <3 %
Height (%) at last evaluation <5 % 10 % 10 % 25 % <3 % 50 % 3 % <5 % <3 %
CC (cm %) at last evaluation 52 cm 50 cm 50 % 75 % 25 % 50 % 50 % 75−90 % nr
Feeding difficulties − + − − − − − − +
GER − − + − − − − − −
Triangular face + − + − + − + + +
Prominent forehead + + + + + − + + +
Small chin + − + − + − − − +
Downslanting corner of mouth − − + − − − − − +
Thin lips + − + − + + − − +
Ear anomalies + + + + − + − + +
Asymmetry − + + + + +a + − +
Clinodactyly V + − − − − − + − −
Syndactyly + − − − − − − − +
Cafè au lait spots − + + − − − nr − nr
Muscular hypotrophy/hypotonia − − + − + − − nr +
Hypospadia − + − − + − − − −
Psychomotor delay − − − − + − − + +
Malformations and pediatric problems Transitory neonatal hypocalcemia Peritoneal simple
mesothelial cyst
– – Epicantus, cryptorchidism,
preputial abnormality
Bilateral epicantus – – –
Other Unique umbilical artery GH deficit – Minor MAF – Paravertebral neuroblastoma – – – –
y years, m months, nr not reported, g grams, CC cranial circumference, GER gastroesophageal reflux, MAF fetal active movements
aFace, ears, upper and lower limbs, tonsillae, kidney
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Table 2 Clinical features of borderline BWS cases
H19/IGF2:IG−DMR KCNQ1OT1:TSS−DMR upd(11)pat
GoM LoM
Cases 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21
Sex F F F F F F F M F M F M M M M M F F F M F
Age at last
evaluation
5.4 y 9 m 10 y 7 y 3.8 y 6.5 y 1.5 y 10 d 1 y 13 m 5 m 2.5 y 5.6 y 2.5 y 4 y 9 y 6 y 1 y 3.5 y 14.5 y 8 m
Miscarriages + − − − − − − − − − − − − − nr nr − − − nr +
Polyhydramnios − − − − + − − − − − − − − − nr nr − − − − −
ART − − − − + − − − + − − − nr − nr nr − − − − −
Monozygous twin − − − − − + + − − − − − − − − − − − − − −
Weeks at delivery 41 37 34 38 39 + 4 36 30 40 + 3 40 + 5 39 41 36 + 4 39 nr nr 39 40 38 41 40 40
Birth weight (g) 3790 4030 2280 2095 4085 2060 770 4590 3880 3150 4430 3130 4275 nr nr 3910 2815 + 3650 4140 −
Birth length (cm) 52 53 nr nr 53 42 31 52 52 51 54 48 49 nr nr 53 48 nr 51 nr nr
CC (cm) nr 38 nr nr 36 33 23 35 33.5 35 38 nr 35 nr nr 36 nr nr 34 nr nr
Postnatalovergrowth − + − − + − − + − + nr − − − − − − + − − −
Hypoglycemia − − + − + − + − − − + − − − − − − − + + −
Macroglossia − − − − − − + − + − + − − + − − − ± + + −
Facial
dysmorphology
− − − − − − + − + − + − − + − − − − + − −
Ear pits/creases + + − − − − − + − − − − − − + − − − − + −
Hemihyperplasia + + + + + + − + + + − + + + + + + + − + +
Facial asymmetry − − + + − + − − − − − − + − + − − + − − −
Exomphalos − − − − − − + − − − − − − − − − − − + − −
Rectum diastasis − − − + − − + + + − − − + − − − − − − − −
Umbilical hernia − − − − − − − + − − + + − − + − − + + − −
Organomegaly − − − − − − − − − − − − − Liver − − − − − − −
Naevus flammeous − − − − − + − + − − − − − − − − − − + − −
Wilms’ tumor/
onset age
4 y − 2.5 y − − − − − − − − − − − − − − − − − −
Convulsions − − − − − − +a − − − − − − − − − − − − − −
Psychomotor delay − − + − − + + − − − − − − − − − − − − − −
Other − − IUGR
cleft palate,
dilated
submeningial
cavities
− − VSD,
PFO
Hypo-
thyroidism
− − − − − PAS − Renal
hypoplasia
Telarca Thyroid
nodule
− − Adrenal
nodule
y years,m months, d days, nr not reported, ART assisted reproductive technologies, g grams, CC cranial circumference, VSD (perimembranous, subaortic) ventricular septal defect, PFO patent foramen ovale, PAS pulmonary arterial stenosis
aParoxysmal tonic upgaze
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mosaic epimutations and UPD, neither technique is per se
sufficient to disclose the entire spectrum of alterations.
Combining these techniques is important, especially in
cases in which methylation levels are near the normal
threshold of control individuals. In addition, the analysis of
tissues other than blood is important for detecting IH pa-
tients who, despite showing a mild phenotype, would bene-
fit from accurate genetic counseling and specific cancer
surveillance programs given their high risk of developing
embryogenetic tumors [25]. In order to detect hidden
mosaicism in BWS/SRS, collection of buccal swabs,
urine, or cells of mesenchymal origin in conjunction
with surgery should be implemented in the practical
molecular work-up being facilitated by the common
need for interventions in childhood to correct macro-
glossia, abdominal wall defects, or severe limb
asymmetry.
We believe that two relevant aspects are at the roots
of the complexity of BWS and SRS molecular diagnosis.
First, the variable degree of methylation at the different
CpGs within the H19/IGF2:IG-DMR region, which was
reported recently in SRS [30] and previously in BWS
[31], requires that the tools of molecular diagnosis ex-
tensively interrogate the differentially methylated CpGs
in order to assure the maximum coverage. This is par-
ticularly true when a single CpG suggests deregulated
methylation. Azzi [30] and Cerrato’s [31] studies found
that CTS1 and CTS7 tend to be correctly methylated in
the presence of deregulated flanking CpGs. In the
present study, we analyzed methylation patterns at the
H19 promoter, A1 and B1 repeats (CTS6) by at least two
approaches, while at B5 repeat (CTS3) and IGF2 by SB
and pyrosequencing, respectively (see Fig. 1). In agree-
ment with Azzi et al. [30], we observed that methylation
recorded at H19 promoter and CTS3 gave overlapping
results, while values at CTS6 may be normally methyl-
ated in patients, suggesting that some sites may be less
representative than others. To provide a key for the in-
terpretation of borderline molecular results obtained by
MS-MLPA, which is one of the most widely applied
tools in BWS/SRS diagnostic laboratories, we first com-
pared the range of methylation levels in controls to
those in affected individuals (Additional file 1: Table S1
and Fig. 3f, g). In patients with SRS, we defined a H19
hypomethylation interval that allowed distinction be-
tween “easy to diagnose,” with values ≤mean −4 SD and
“borderline” values, with values between mean −3 SD
and mean −4 SD. In SRS, we succeeded in defining a
“disease range” of H19 LoM, i.e., values that were never
observed in normal controls, although with a narrow
threshold [23].
Average methylation levels should be interpreted
critically by assessing the values for each probe, as a
patient may show normal indexes for one probe and
aberrant ones for another probe. In these cases, the
use of other techniques or expanding the analysis to
tissues other than blood becomes necessary [31]. The
inclusion of different methods allows zooming in on
the entire region to be investigated, which enhances
the diagnostic ability in borderline cases. The second
diagnostic pitfall is the occurrence of low-grade mo-
saicism in BWS carriers of upd(11)pat. These patients
are at risk of misdiagnosis when only methylation
Fig. 5 Variable clinical features of SRS and BWS patients with low
mosaic methylation levels or upd. a Face and full body of SRS-4 at
age 8 years, SRS-5 at 2.5 years, and SRS-6 at 6 years of age. No overt
facial dysmorphisms are visible in SRS-4; frontal bossing is marked in
SRS-5, while SRS-6 shows only hemihypoplasia of the left lower limb.
b Frontal face of BWS-1 at 5.4 years of age, showing mild but typical
features, BWS-6 at 2 years and 8 months, showing no facial dysmorphisms
and only pronounced hemihyperplasia of the lower right limb, BWS-16 at
9 years and BWS-17 at 6 years with visible hemihyperplasia of lower left
and right limb, respectively
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values are analyzed, as more than one CpG may fall
within the normal range despite the use of different
technical approaches. When the mean MS-MLPA
blood values fall within 1 SD, detection of upd is rec-
ommended using microsatellite segregation or, even
better, SNP array, as the latter method covers a more
extensive region and is therefore more sensitive. SNP
array validation in some cases and buccal swab in
others were crucial for providing a conclusive mo-
lecular diagnosis in our borderline cases.
Without the technological stock set up for the molecu-
lar tests, 30 patients with borderline methylation levels in
our SRS and BWS cohorts would have remained “sus-
pected.” Considering the two opposite growth disorders
separately, 9 SRS cases (20 %) and 21 “borderline” BWS
cases (more than 10 %) were among the total 43 and 206
molecularly diagnosed cases, respectively.
The fact that the fraction of SRS cases that could be
molecularly diagnosed was higher than that of BWS
cases could be ascribed to the clinical phenotype, which
in general was more complete in SRS and hence pro-
moted the use of genetic testing. This view is exempli-
fied by SRS-1, SRS-5, and SRS-9 cases who all displayed
strongly suggestive clinical features, although they ob-
tained molecular diagnosis only by comparative tech-
niques on blood and/or buccal swabs. It is worth to
underline that SRS-5 developed a paravertebral neuro-
blastoma, as tumor occurrence has been very rarely re-
ported in SRS [32].
Apart from this difference, both SRS and BWS borderline
cases showed a wide clinical expressivity ranging from overt
to incomplete or atypical phenotypes.
A case well exemplifying the challenges of clinical diagno-
sis and the utility of complementary molecular diagnostic
technologies, when a suggestive phenotype is lacking, is
SRS-6 who did not display the typical SRS facial dysmorph-
isms (Fig. 5a) or growth retardation (Table 1) and was re-
ferred to our laboratory for hemihyperplasia (i.e., within the
BWS spectrum). The molecular diagnosis, at cut-off level
by SB and MS-MLPA and then supported by pyrosequenc-
ing, allowed revision of the patient’s clinical condition,
which was defined as hemihypoplasia (i.e., within the SRS
spectrum). The revised diagnosis implied the possibility of
waiving the cancer surveillance protocol generally pre-
scribed in IH/BWS cases, which consists of cancer plasma
marker measurement and abdominal ultrasound every
3 months during the first 10 years of life. Moreover, this
case well represents the seldom encountered “mixed phe-
notypes” bridging the two opposite growth disorders.
The clinical features of the genetically borderline BWS
cases, showing intermediate aberrant methylation values
(between mean ±1 SD and mean ±3 SD), were far from
the classic phenotypes depicted in cases with a definite
molecular diagnosis. Overgrowth at birth, which is usually
present in >95 % of BWS patients, was detected in 31 % of
borderline cases, and macroglossia, which is the trait
described as most indicative of BWS clinical diagnosis,
occurred in 33 % of this cohort versus the 70–90 %
reported previously [8, 9]. BWS-3 and BWS-7 showed
atypical phenotypes and needed other tests, such as array
CGH and exome sequencing, to exclude the concurrence
of other molecular defects. BWS-7 manifested paroxysmal
tonic upgaze, a peculiar sign in BWS patients, and devel-
oped persistent hypoglycemia. BWS-3 showed IUGR,
postnatal growth retardation up to late infancy, and exter-
nal hydrocephaly, a sign recently highlighted in a few
BWS cases [33]. In this patient, the BWS phenotype was
manifested later, when the hemihyperplasia became appar-
ent and Wilms’ tumor developed. Another borderline
patient finally diagnosed with H19/IGF2:IG-DMR de-
fect, BWS-1, had Wilms’ tumor, and the upd(11)pat
carriers BWS-18 and BWS-21 had a benign thyroid and
adrenal nodule, respectively.
The widespread occurrence of hemihyperplasia often
associated with no or a few other signs supports the
observation/hypothesis that a low mosaicism rate, as
detected in a few of our upd(11)pat carriers, is likely
responsible for the high fraction of IH cases remaining
without molecular diagnosis.
As to the wide clinical expressivity of the borderline
cases, concomitant factors such as multilocus methyla-
tion disturbances (MLID) [34], which may determine a
relatively more severe and atypical phenotype than that
of only 11p15 epimutated cases, are possibly implicated
in borderline BWS cases, impairing (epi)genotype-pheno-
type correlations [35]. As it has been recently shown, MLID
can be exhaustively detected by applying whole genome
methylation approaches [36, 37] that although not yet per-
formed in the diagnostic work-up, should be considered as
further proceeding as highlighted in our BWS flowchart
(Fig.4b) in cases who bear a primary epimutation, including
the borderline ones. Another proceeding suitable for BWS
cases without molecular diagnosis, especially familial cases,
is represented by exome targeted deep sequencing (Fig. 4b)
aiming at identifying mutations in genes encoding trans-
acting regulators of imprinted loci [38].
The key message of our work is that efforts should be
made to solve suspected cases in the SRS and BWS
spectrum through various combinations of 11p15.5-tar-
geted and cytogenomic techniques, not only for research
purposes but also for the current diagnostic activity.
Conclusions
MS-MLPA or another eligible technique for the
assessment of H19/IGF2:IG-DMR and H19/IGF2:IG-
DMR /KCNQ1OT1:TSS-DMR epigenetic alterations
may be the starting point of SRS and BWS genetic
testing. The MS-MLPA results can orient the molecular
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geneticist in the application of cytogenomic techniques
such as array CGH, SNP array, karyotyping, or targeted
FISH to search for other alterations and to detect the
slightest mosaicism levels within the limits of the available
up-to-date methods. For BWS, besides upd(11)pat,
chromosomal rearrangements may be at the basis of
simultaneous H19/IGF2:IG-DMR and KCNQ1OT1:TSS-
DMR dysregulation, featuring a rare condition with a
recurrence risk of 50 %. Finally, CDKN1C mutations
should be investigated, not only in all familial cases but
also in sporadic cases presenting with omphalocele, both
for research and diagnostic purposes.
The diagnostic detection rate could also be improved by
introducing the analysis of tissues other than blood into
the routine follow-up, as suggested by the occurrence of
low-rate mosaicism and the variable degree of methylation
in different tissues. The development of more sensitive
technical tools should facilitate the identification of cases
that may remain undiagnosed because of mosaicism, a
distinctive feature of epigenetic disorders.
Methods
Subjects
A total of 147 patients aged 6 months to 20 years present-
ing with IUGR, mild to severe postnatal growth retardation
and asymmetry, and facial phenotypes suggestive or SRS,
were referred to our laboratory for molecular diagnosis. A
sample of 450 patients, ranging from newborns to patients
47 years of age with a clinical diagnosis of BWS, was proc-
essed in parallel. The BWS cohort included a subset of 83
patients diagnosed with IH. The criteria for clinical diagno-
sis of SRS were those established in 2007 by Netchine [39]
and recently updated by Azzi (2015) [23] and for BWS,
those indicated by Choufani [40]. In all cases, informed
consent for genetic testing was signed by the probands or
their parents. DNA was extracted from peripheral blood
lymphocytes (Automated extractor Tecan, Männedorf,
Switzerland and Promega kit, Madison, WI) of the trios of
probands and parents; whenever possible, epithelial buccal
cells were collected (Oragene tubes OG-575), and DNA
was extracted according to the manufacturer’s protocol
(Oragene DNA kit, DNA Genotek Inc., a subsidiary of
OraSure Technologies).
SRS patients were investigated for upd(7)mat and
H19/IGF2:IG-DMR LoM and 11p15.5 micro-
rearrangements; the BWS cohort and the set of IH
cases were tested for UPD11 and H19/IGF2:IG-DMR
and KCNQ1OT1:TSS-DMR defects. In case of uncer-
tain results, a different tissue (epithelial buccal cells)
was examined.
The study protocol was approved by the Research Ethics
Board of Istituto Auxologico Italiano, Milan, Italy, and all
subjects provided written informed consent.
Uniparental disomy of chromosome 7
A panel of 20 microsatellites, spanning the whole
chromosome from pter to qter, D7S517(7p22.2),
D7S641(7p21.3), D7S2464(7p21.3), D7S513(7p21.3),
D7S507(7p21.1), D7S503(7p21.1), D7S2493(7p15.3),
D7S2525(7p15.2), D7S2496(7p14.3), D7S519(7p13),
D7S2422(7p12.1), D7S2467(7p12.1), D7S506(7p12.1),
D7S1870(7q11.23), D7S486(7q31.2), D7S640(7q32.3),
D7S661(7q35), D7S636(7q36.1), D7S798(7q36.2),
D7S2465(7q36.3) was selected for segregation analysis
from parents to SRS probands. PCR analyses were per-
formed using fluoresceinated primers and PCR products
were separated using an automated ABI 310 sequencer.
Uniparental disomy of chromosome 11
The 11 polymorphic loci (D11S1363, D11S1318,
D11S1984, D11S4177, D11S4046, TH, D11S4124,
D11S4146, D11S1338, D11S1323, and D11S1760) from
11p15.5 to 11p14 were used for segregation analysis
from parents to BWS and IH probands. Mosaicism
occurrence and level were assessed by calculating the
ratio between maternal and paternal peak areas as
reported previously [29]. Additional 11p centromeric
markers D11S4116, D11S4121, D11S902, and D11S935
and the 11q markers D11S1777, D11S4191, D11S1883,
D11S987, D11S4147, D11S908, D11S4094, and D11S968
were used to establish isodisomy extent in upd carriers.
H19 and KvDMR1 methylation profiles
MS-MLPA technique
The MCR-Holland kit, ME-030 BWS/RSS (MRC Holland,
Amsterdam, The Netherlands) was used according to the
kit instructions on test and control samples (in the ratio of
one control for every seven patients). DNA was processed
in parallel with and without digestion with the methyla-
tion sensitive HhaI enzyme to detect both methylation
deregulation and copy number variation. Data analysis
was performed using the Coffalyser.net software v.
131211, which provides two outputs, one related to CNVs
and the other to the methylation status. The latter is
defined for each single probe by the ratio of digested to
undigested DNA, referring each test sample to positive
and negative references.
Pyrosequencing
Sodium bisulphite conversion of DNA (500–700 ng)
was performed by the EZ DNA Methylation Kit (Zymo
Research Corporation, Orange, CA). ICR1, H19 pro-
moter, IGF2-DMR2 (11p15.5 telomeric cluster), and
ICR2 (11p15.5 centromeric cluster) PCR analyses were
performed on bisulphite-treated DNA using forward
and reverse primers, one of which was biotinylated
[27]. Pyrosequencing experiments were performed
using specific sequencing primers to quantify four
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CpG sites for ICR1, three for the H19 promoter, six
for DMR2, and four for ICR2. PCR and sequencing
primers were as follows:
ICR1 Fw: 5′-TGGGTATTTTTGGAGGTTTTTTT-3′;
ICR1 Rev: 5′bio-AACTTAAATCCCAAACCATAACA-3′;
ICR1 Seq: 5′-GTTTYGGGTTATTTAAGTTA-3′ (hg19,
chr11:2020978-2021291)
H19 promoter Fw: 5′-TGGTGTTTTTTGAGGGGA
GATA-3′; Rev: 5′bio-CACCTCCRCCCTAAACAAT-3′;
H19 prom Seq: 5′-GGGGTAATGTTTAGTTTTGT-3′
(hg19 , chr11:2019185-2019372)
DMR2 Fw: bio 5′-GGAAGAGYGTGGAGAGTAGG
TATTTGTTG-3′; DMR2 Rev: 5′ACTCACTTCCRAT
TACTAACCATCTC-3′; DMR2 Seq: 5′-CTCRAACTCC
TTAACAAAC-3′ (hg19 chr11:2154216-2154503)
ICR2 Fw: 5′-TTGTTTATAAGGTGTAGATGGGAG-3′;
Rev: 5′-TCTCCCAAACTCTCCTCAAC-3′; ICR2 Seq: 5′-
TAGGTTAGGTTGTATTGTTG-3′ (hg19 chr11:2720465-
2720669)
Quantitative DNA methylation analyses were performed
using a Pyro Mark ID instrument (QIAGEN, Silicon Valley,
CA) in the PSQ HS 96 System with the PyroGold SQA re-
agent kit (Diatech Pharmacogenetics srl, Jesi, Italy) accord-
ing to the manufacturer’s instructions. Raw data were
analyzed using Q-CpG software v1.0.9 (Qiagen srl), which
calculates the ratio of converted C’s (T’s) to unconverted
C’s at each CpG, giving the percentage of methylation.
For each sample, the methylation value represents the
mean between at least two independent PCR and pyrose-
quencing experiments. Methylation values were expressed
as percentages, and the results were analyzed keeping into
account the following ranges of control individuals: ICR1,
40–52 %; H19 promoter, 44–54 %; DMR2, 41–52 %; and
ICR2, 39–50 %.
Southern blot analysis
DNA methylation of H19/IGF2:IG-DMR (hg19:
chr11:2022881-2023267 (left probe), chr11:2020629-
2021022 (right probe)) and KCNQ1OT1:TSS-DMR
(chr11:2722937-2723377) was analyzed by Southern
blot hybridization of H19-DMR (provided by Prof. A.
Riccio, CNR Institute of Genetics and Biophysics,
Naples) and KvDMR1 probes to genomic DNA (7 ug)
digested with Csp6I/HpaII and BamHI/NotI restriction
enzymes, respectively [18]. Filters were washed for
20 min in 2× SSC/0.1 % SDS at room temperature,
15 min in 0.5× SSC/0.1 % SDS at 60 °C and 2 min in
0.1× SSC at room temperature and subject to autora-
dioradiography. For each single experiment, a negative
(unaffected) and a known positive (e.g., a previously
tested positive sample) control DNAs were included as
internal control references. Autoradiography films were
scanned at maximum resolution and signal intensities were
quantified using ImageJ software (http://imagej.nih.gov/ij/,
version 1.50b). For each lane, the intensities of H19/
IGF2:IG-DMR (1.7, 1.4, 0.7, 0.5, and 0.4 kb) and
KCNQ1OT1:TSS-DMR (6 and 1.8 Kb) bands were
quantified to calculate methylation index values (MI)
according to Lennertz (2010) [41]. A reference methyla-
tion index range was obtained by calculating MI of 50
(H19/IGF2:IG-DMR) and 40 (KCNQ1OT1:TSS-DMR) un-
affected individuals. Diagnostic threshold was set as mean
value ±2 SD: H19/IGF2:IG-DMR (SRS LoM <44; BWS
GoM >60), KCNQ1OT1:TSS-DMR (BWS LoM <43).
SNP array
SNP array analysis was performed using the Human
OmniExpress-12 Bead Chip (Illumina Inc., San Diego,
CA) containing 731,442 loci derived from phases I, II, and
III of the International HapMap project. A total of 200 ng
of genomic DNA (50 ng/μl) for each sample was proc-
essed according to Illumina’s Infinium HD Assay protocol.
Normalization of raw image intensity data, genotype clus-
tering, and individual sample genotype calls were per-
formed using Illumina’s GenomeStudio software v2011.1
(cnvpartition 3.1.6). The CNV calls were determined using
generalized genotyping methods implemented in the
PennCNV program. The CNVs were mapped to the
human reference genome hg19 and annotated with the
UCSC RefGene. CNVs identified in this study that over-
lapped with CNVs reported in the Database of Genomic
Variants (DGV) (http://projects.tcag.ca/variation) were
not considered.
Additional files
Additional file 1: Table S1. Normal methylation ranges and thresholds
calculated on different sets of healthy individuals by Southern blot, MS-MLPA,
and pyrosequencing. A) Southern blot methylation thresholds calculated by
densitometry on a set of 50 and 40 Italian healthy controls for H19/IGF2:IG-
DMR and KCNQ1OT1:TSS-DMR, respectively, B) MS-MLPA range of methylation
ratios defined on a set of 50 Italian healthy controls, and C) pyrosequencing
methylation range (in percentage) obtained by control individuals. For details,
see the “Methods” section. (PDF 14 kb)
Additional file 2: Table S2. SRS and BWS patients who achieved
molecular diagnosis by different techniques. Column 2 indicates the
number of patients for SRS and BWS, who received a positive molecular
diagnosis, apart from CDKN1C mutated patients; column 4 reports the
number of patients with a definite positive test and a borderline test. In
column 5, the investigated defect is reported, and in column 6, the
number of patients for each mechanism. The number of cases tested for SB,
MS-MLPA, four pyrosequencing probes, microsatellite analysis, and SNP array
are reported in the following columns. Some cases with definite result were
replicated by MS-MLPA and pyrosequencing for their set up. The last column
indicates the cases submitted to SNP array to characterize chromosomal
rearrangements (rows 5 and 6) or to disclose low mosaicism for upd(11)pat
(row 9). The table does not refers to the outcome of the test.*Numbers in-
clude three H19/IGF2:IG-DMR GoM and four H19/IGF2:IG-DMR GoM+
KCNQ1OT1:TSS-DMR LoM cases who needed karyotyping /FISH analysis, three
of which reported [18, 28]. (PDF 38 kb)
Additional file 3: Table S3. Comparison of methylation data obtained
by Southern blot, pyrosequencing, and MS-MLPA of all borderline (BL)
SRS and BWS cases. Methylation indexes (MI) and values obtained by SB,
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pyrosequencing, and MS-MLPA techniques of (A) SRS borderline LoM
(H19/IGF2:IG-DMR), (B) BWS borderline GoM (H19/IGF2:IG-DMR), (C) BWS
borderline LoM (KCNQ1OT1:TSS-DMR), (D) BWS borderline upd GoM (H19/
IGF2:IG-DMR), (E) BWS borderline upd LoM (KCNQ1OT1:TSS-DMR), and (F)
SRS borderline case 1 (blood vs buccal swab) (H19/IGF2:IG-DMR). BWS
borderline cases (12, 13, 14, 15, 16, and 21) also investigated by SNP array.
Methylation data of all techniques were calculated as described in the
“Methods” section. Missing data are indicated as nd (not detected). Asterisks
(*) indicate the mean of at least two experiments. Diagnostic thresholds (see
text, the “Methods” and Additional file 1 for exhaustive explanations) are
shown on the right side. MS-MLPA thresholds obtained by adding or
subtracting (to the average value) three (in black) or two (in red) standard
deviations are also displayed. Aberrant methylation values are bolded and
underlined while methylation values meeting less stringent criteria (±2 SD)
are in red characters. (PDF 57 kb)
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